Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 15.56
ABMD's Cash-to-Debt is ranked higher than
65% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. ABMD: 15.56 )
Ranked among companies with meaningful Cash-to-Debt only.
ABMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 13.95  Med: No Debt Max: No Debt
Current: 15.56
Equity-to-Asset 0.87
ABMD's Equity-to-Asset is ranked higher than
82% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ABMD: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
ABMD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.52  Med: 0.86 Max: 0.95
Current: 0.87
0.52
0.95
Debt-to-Equity 0.03
ABMD's Debt-to-Equity is ranked higher than
89% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 0.29 vs. ABMD: 0.03 )
Ranked among companies with meaningful Debt-to-Equity only.
ABMD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.04
Current: 0.03
0
0.04
Interest Coverage N/A
ABMD's Interest Coverage is ranked higher than
74% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 73.23 vs. ABMD: N/A )
Ranked among companies with meaningful Interest Coverage only.
ABMD' s Interest Coverage Range Over the Past 10 Years
Min: 506.67  Med: No Debt Max: No Debt
Current: N/A
Piotroski F-Score: 5
Altman Z-Score: 51.20
Beneish M-Score: -2.37
WACC vs ROIC
-0.08%
34.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 21.48
ABMD's Operating Margin % is ranked higher than
88% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.45 vs. ABMD: 21.48 )
Ranked among companies with meaningful Operating Margin % only.
ABMD' s Operating Margin % Range Over the Past 10 Years
Min: -61.9  Med: 2.88 Max: 21.48
Current: 21.48
-61.9
21.48
Net Margin % 16.13
ABMD's Net Margin % is ranked higher than
78% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. ABMD: 16.13 )
Ranked among companies with meaningful Net Margin % only.
ABMD' s Net Margin % Range Over the Past 10 Years
Min: -69.44  Med: 2.59 Max: 49.36
Current: 16.13
-69.44
49.36
ROE % 17.31
ABMD's ROE % is ranked higher than
77% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. ABMD: 17.31 )
Ranked among companies with meaningful ROE % only.
ABMD' s ROE % Range Over the Past 10 Years
Min: -37.95  Med: 3.05 Max: 49.44
Current: 17.31
-37.95
49.44
ROA % 14.68
ABMD's ROA % is ranked higher than
85% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.49 vs. ABMD: 14.68 )
Ranked among companies with meaningful ROA % only.
ABMD' s ROA % Range Over the Past 10 Years
Min: -32.2  Med: 2.49 Max: 41.81
Current: 14.68
-32.2
41.81
ROC (Joel Greenblatt) % 103.76
ABMD's ROC (Joel Greenblatt) % is ranked higher than
93% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 6.15 vs. ABMD: 103.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABMD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -206.12  Med: 28.38 Max: 171.62
Current: 103.76
-206.12
171.62
3-Year Revenue Growth Rate 31.20
ABMD's 3-Year Revenue Growth Rate is ranked higher than
91% of the 239 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. ABMD: 31.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABMD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -30.6  Med: 14.4 Max: 51.9
Current: 31.2
-30.6
51.9
3-Year EBITDA Growth Rate 102.20
ABMD's 3-Year EBITDA Growth Rate is ranked higher than
97% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 6.30 vs. ABMD: 102.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ABMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -56  Med: 12.85 Max: 136.2
Current: 102.2
-56
136.2
3-Year EPS without NRI Growth Rate 86.60
ABMD's 3-Year EPS without NRI Growth Rate is ranked higher than
95% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. ABMD: 86.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ABMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.8  Med: 18.6 Max: 304.6
Current: 86.6
-57.8
304.6
» ABMD's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ABMD Guru Trades in Q3 2016

Jim Simons 660,223 sh (+6.19%)
Joel Greenblatt Sold Out
PRIMECAP Management 4,708,590 sh (-5.95%)
Columbia Wanger 80,790 sh (-79.23%)
» More
Q4 2016

ABMD Guru Trades in Q4 2016

Steven Cohen 92,600 sh (New)
Chuck Royce 10,000 sh (New)
Columbia Wanger 311,535 sh (+285.61%)
PRIMECAP Management 4,676,630 sh (-0.68%)
Jim Simons 523,900 sh (-20.65%)
» More
Q1 2017

ABMD Guru Trades in Q1 2017

George Soros 2,400 sh (New)
Chuck Royce 17,000 sh (+70.00%)
Jim Simons 668,700 sh (+27.64%)
Columbia Wanger Sold Out
PRIMECAP Management 4,636,590 sh (-0.86%)
Steven Cohen 56,700 sh (-38.77%)
» More
Q2 2017

ABMD Guru Trades in Q2 2017

Jim Simons 893,223 sh (+33.58%)
Chuck Royce 20,000 sh (+17.65%)
Steven Cohen Sold Out
George Soros Sold Out
PRIMECAP Management 4,434,088 sh (-4.37%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ABMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2017-06-30 Sold Out 0.01%$120.73 - $145.94 $ 163.9622%0
George Soros 2017-03-31 New Buy0.01%$104.1 - $125.26 $ 163.9641%2,400
Joel Greenblatt 2016-09-30 Sold Out $109.83 - $129.89 $ 163.9637%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:MASI, NYSE:VAR, NAS:IART, NYSE:TFX, NYSE:PEN, NAS:NUVA, NYSE:GMED, NYSE:NVRO, NAS:INGN, NAS:SPNC, NAS:MDXG, NYSE:ITGR, NAS:CNMD, NAS:BABY, NAS:CSII, NAS:KTWO, NAS:XENT, NYSE:CRY, NAS:TCMD, NAS:AXGN » details
Traded in other countries:AIO.Germany,
Headquarter Location:USA
Abiomed Inc is a medical device company. It provides mechanical circulatory support devices to aid heart recovery to heart failure patients.

Abiomed provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are primarily used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. They work by improving blood flow to coronary arteries or temporarily performing the pumping function of the heart. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.

Top Ranked Articles about Abiomed Inc

Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure
Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former Chief Financial Officer as Consultant
Heart Recovery Patients Visit Capitol Hill to Advocate for Lifesaving Cardiovascular Technology
Abiomed to Present at the Jefferies Healthcare Conference
Abiomed Introduces 3rd Generation Impella CP® Heart Pumps at SCAI 2017
Abiomed Announces First Patient Enrolled in STEMI DTU Feasibility Study
Abiomed Fourth Quarter Fiscal 2017 Earnings and Conference Call Notification
Abiomed Marks Grand Opening of Newly-Expanded Headquarters in Danvers, Massachusetts

Governor Baker joins heart recovery leader for grand opening of new manufacturing and training space that represents major investment in Massachusetts

DANVERS, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Massachusetts Governor Charlie Baker today joined Abiomed – a leading provider of breakthrough heart support and recovery technologies – for the grand opening of its newly expanded global headquarters in Danvers.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a85c5b1d-6799-4fc6-b6bb-40e104632b3a. With the expansion, Abiomed more than doubles the size of its headquarters from 60,000 square feet to 160,000 square feet adding new research and manufacturing capabilities, along with the new Heart Recovery Institute for clinical education – a cutting edge training facility.  It represents a more than $40 million investment in Massachusetts for education, manufacturing, and training. “With Massachusetts-based companies like Abiomed helping to lead the way, the Commonwealth continues to be a global leader in health care, innovation and technology,” said Governor Charlie Baker. “I am pleased to continue to witness the growth of a company that has invested in Massachusetts for more than 35 years and we look forward to continuing to work together to create jobs and develop the state’s innovation economy.” Abiomed broke ground on the construction in June 2015 and has since added more than 150 engineering and manufacturing jobs to the site. The company now has more than 400 employees in Massachusetts, over 700 in the United States, and globally is nearing 1,000. Abiomed is also expanding its capacity in Berlin and Aachen, Germany and Tokyo, Japan. “Today we recognize 35 years of dedication and hard work by all the people who made this possible – from employees, to customers, to patients, to investors,” said Abiomed President, Chairman and CEO Mike Minogue. “We celebrate our Patients First culture and this investment in our future. We are proud to add new clinical, engineering and manufacturing jobs in Massachusetts because it will ensure faster innovation, quality, and compliance. Our mission is to help recover hearts; now we have the manufacturing infrastructure to support enough patients to fill Fenway Park each year.” During the event, Abiomed also recognized two cardiac patients that benefited from the company’s lifesaving technology. Conference rooms were named in honor of milestone patients Rogelio Landin of Detroit, MI and Howard Gaynor of Hartford, CT. Robert Pasquariella, a patient treated with the Impella device from Everett, Mass., also attended the event with his son Bobby who was part of the construction team that worked on the expansion. Abiomed has been in Massachusetts since 1981, securing three FDA approvals and earning 264 patents with another 237 pending. The company recently announced that it has supported more than 50,000 patients in the U.S. with Impella®, the world’s smallest heart pump – which can help the heart rest, recover and in some cases, heal. Abiomed is the only company with FDA approval for heart recovery and the Impella is the only FDA-approved percutaneous hemodynamic support device approved safe and effective for the treatment of high risk patients, and patients with Acute Myocardial Infarction Cardiogenic Shock (AMICS). ABOUT IMPELLA HEART PUMPS The Impella 2.5®, Impella CP® and Impella 5.0® are FDA-approved heart pumps used to treat heart attack patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella 2.5 and Impella CP devices are also approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. Abiomed's right-side heart pump, the Impella RP® device, is approved to treat certain patients experiencing right heart failure. To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: www.protectedpci.com. FORWARD-LOOKING STATEMENTS This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
Media Contact
Laura Wareck
[email protected] | 978-660-9587
Adrienne Smith
[email protected] |781-277-1170

Read more...
First-Ever Presentation on Abiomed’s Impella® Quality (IQ) Assurance Program and Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery at the 2017 American College of Cardiology Scientific Session

- Real-World Data Representing 15,259 Patients WASHINGTON, March 19, 2017 (GLOBE NEWSWIRE) -- Data from Abiomed’s (NASDAQ:ABMD) Impella® Quality (IQ) Assurance Program, which includes the IQ Database and cVAD Registry, was presented today as late-breaking Featured Clinical Research at the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington, D.C. These data were derived from the IQ Database documenting the real-world treatment of approximately 50,000 U.S. patients, with a subset of 15,259 Acute Myocardial Infarction Cardiogenic Shock (AMICS) patients. The Impella heart pump results indicate an association between the use of best practice protocols and improved survival and native heart recovery, as compared to inconsistent treatment or inexperienced hospitals. The Abiomed IQ Assurance Program is a real-world collection of clinical information derived from the treatment of patients with Impella devices since 2008. Trends in the observational IQ Database, combined with information from Abiomed’s Institutional Review Board (IRB)-approved cVAD Registry have helped identify best practices and protocols that are associated with improved survival and native heart recovery in hospitals using Impella devices. Best practice protocols include: Unloading the left ventricle of the heart (Door to Unload or DTU) with Impella before percutaneous coronary intervention (pre-PCI) in the setting of cardiogenic shockReducing the escalation of inotrope therapyUtilizing hemodynamic monitoring for escalation and weaning during supportExperienced physicians implanting Impella heart pumps Results from the IQ Database reveal that since the Impella line of heart pumps received Pre-Market Approval (PMA) from the United States Food and Drug Administration (FDA) in April 2016 for use in treating AMICS5, there has been an observed 14 percent relative improvement in survival as compared to the prior year. In 2016, there were 89,000 AMICS cases nationwide, and approximately 5,000 or about 6 percent, were treated with Impella heart pumps. This compares with approximately 35,600 or 40 percent treated with the intra-aortic balloon pump (IABP), even though randomized controlled trials show no hemodynamic augmentation or survival benefit for IABP patients in AMICS1,2. Though First 510(k) cleared in 1976 as a result of already being on the market, the IABP is not FDA approved as safe and effective for the AMICS indication. “The FDA deemed Impella devices safe and effective in the U.S. for cardiogenic shock less than one year ago, which has allowed us to collaborate with hospitals to expand education on hemodynamic science and share best practices to achieve native heart recovery across the country. We are pleased to see improvements of 14 percent this year and recognize the opportunity to further impact and improve the outcomes of thousands of patients with the lessons learned by the most advanced centers and physicians,” said Seth Bilazarian, MD, FACC, FSCAI, Chief Medical Officer, Abiomed. The data presented today also included new data from the Detroit Cardiogenic Shock Initiative (DCSI), which is an unprecedented collaboration between five heart hospitals in Detroit. The presentation by study principal investigator William W. O’Neill, MD, FACC, FSCAI, Medical Director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit, highlighted the treatment of 37 patients utilizing these best practices and protocols derived from Abiomed’s IQ Assurance Program and our most experienced heart hospitals. Applying these systematic best practices, DCSI hospitals showed an increase in cardiogenic shock survival rates from 51 percent baseline to 84 percent, with 100 percent of survivors discharged home with their native heart. “These results validate earlier studies from the cVAD Registry that early circulatory support is critical for survival and heart recovery in cardiogenic shock,” said Dr. O’Neill. “We are proud of the positive results of our unprecedented collaboration. By sharing our best practice protocols, we remain committed to improving shock outcomes in Detroit and around the world.”  Impella SitesSurvivalSurvival
Improvement
(Absolute %)Survival
Improvement
(Relative %)Standardized
Protocols for Heart
RecoveryIQ Database n=15,5291,010 Hospitals58%7%14%NoTop 20% IQ n=3051158
Hospitals76%25%50%YesDetroit CSI
n=375 Hospital Systems84%33%65%Yes These new data support prior publications with percutaneous heart pumps (such as Impella) supporting cardiogenic shock patients published in JACC (National trends in the utilization of short-term mechanical circulatory support)3 and the Journal of Interventional Cardiology (Use of Impella 2.5 in Acute Myocardial Infarction complicated by Cardiogenic Shock)4 representing nearly 12,000 Medicare/insurance patients and 154 cVAD Registry patients respectively. The mission of the IQ Assurance Program is to improve real-world outcomes in Protected PCI and cardiogenic shock patients through training, education and utilization of clinical guidelines, protocols and best practices derived from observational quality assurance data (IQ), IRB approved registry data (cVAD) and IDE approved FDA studies. The points reflected specifically in the IQ Database, as compared to the IQ Program, which includes the cVAD Registry and FDA studies, are not statistically-powered or pre-specified, and no statistical conclusions can be drawn from the observational database. "Abiomed has invested to create the largest high-risk PCI6 and cardiogenic shock database of real-world evidence," said Michael R. Minogue, Abiomed President, Chairman and Chief Executive Officer. "We believe that by sharing our data-driven insights and clinical expertise, along with our 24x7 onsite and on-call support, we can help hospitals improve outcomes and reduce costs for the sickest patients in the system." ABOUT IMPELLA HEART PUMPS The Impella 2.5®, Impella CP® and Impella 5.0® are FDA-approved heart pumps used to treat heart attack patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella 2.5 and Impella CP devices are also approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. Abiomed's right-side heart pump, the Impella RP® device, is approved to treat certain patients experiencing right heart failure. To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: www.protectedpci.com. The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Recovering Hearts. Saving Lives. are registered trademarks of ABIOMED, Inc. in the U.S. and in certain foreign countries. ABOUT ABIOMED 
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com. FORWARD-LOOKING STATEMENTS This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events. Wayangankar, S. et. al J Am Coll Cardiol. Int CATH-PCI Registry.Prondzinsky R. et al. Jn Critical Care Medicine IABP-SHOCK I 2010 – Clinicaltrial.gov # NCT00469248.Stretch, R. National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. J Am Coll Cardiol. 2014 Oct 7;64(14):1407-15. doi: 10.1016/j.jacc.2014.07.958.O’Neill, W. The current use of Impella 2.5 in Acute Myocardial Infarction complicated by Cardiogenic Shock: Results from the USpella Registry. J Interv Cardiol. 2014 Feb; 27(1): 1–11. doi: 10.1111/joic.12080.The data submitted to the FDA in support of the PMA included an analysis of 415 patients from the RECOVER 1 study and the U.S. Impella registry (cVAD Registry™), as well as an Impella literature review including 692 patients treated with Impella from 17 clinical studies. A safety analysis reviewed over 24,000 Impella treated patients using the FDA medical device reporting ("MDR") database, which draws from seven years of U.S. experience with Impella.
In addition, the Company also provided a benchmark analysis of Impella patients in the real-world Impella cVAD registry vs. these same patient groups in the Abiomed AB5000/BVS 5000 Registry. The Abiomed BVS 5000 product was the first ventricular assist device (VAD) ever approved by the FDA in 1991 based on 83 patient PMA study. In 2003, the AB5000 Ventricle received FDA approval and this also included a PMA study with 60 patients.
For this approval, the data source for this benchmark analysis was a registry ("AB/BVS Registry") that contained 2,152 patients that received the AB5000 and BVS 5000 devices, which were originally approved for heart recovery. The analysis examined by the FDA used 204 patients that received the AB5000 device for the same indications. This analysis demonstrated significantly better outcomes with Impella in these patients. The Company believes this is the most comprehensive review ever submitted to the FDA for circulatory support in the cardiogenic shock population.The Impella 2.5 heart pump received FDA PMA approval to treat certain elective and urgent high risk PCI patients in March of 2015. The Impella CP heart pump was subsequently approved to treat that patient population in December 2016. The data underpinning the FDA’s approval of the Impella 2.5 device included U.S. clinical trial data from the PROTECT I FDA safety study and the PROTECT II randomized clinical trial.
Additionally, the PMA submission for the Impella 2.5 device included an analysis of 637 high risk patients, from 49 separate centers, enrolled in the cVAD Registry (formerly known as the U.S. Impella registry), which now contains nearly 3,000 patient records and includes Institutional Review Board (IRB) approval, complete data monitoring and Clinical Events Committee adjudication. The Impella 2.5 PMA submission also included clinical and scientific supporting evidence from more than 215 publications, totaling 1,638 Impella 2.5 patients and incorporated a medical device reporting (MDR) analysis from 13,981 Impella 2.5 patients. In additional to this comprehensive data set, the FDA’s PMA approval for the Impella CP device included its consideration of 72 high risk Impella CP patients from the CVAD Registry, as well as an additional 637 Impella 2.5 device patients.
**For further information please contact:

Adrienne Smith
Senior Director, Public Relations and Corporate Communications
978-646-1553
[email protected]

Ingrid Goldberg
Director, Investor Relations
978-646-1590
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 96.43
ABMD's PE Ratio is ranked lower than
93% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.71 vs. ABMD: 96.43 )
Ranked among companies with meaningful PE Ratio only.
ABMD' s PE Ratio Range Over the Past 10 Years
Min: 22.02  Med: 98.47 Max: 615.5
Current: 96.43
22.02
615.5
PE Ratio without NRI 96.43
ABMD's PE Ratio without NRI is ranked lower than
93% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 31.10 vs. ABMD: 96.43 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABMD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 22.02  Med: 98.47 Max: 615.5
Current: 96.43
22.02
615.5
Price-to-Owner-Earnings 90.48
ABMD's Price-to-Owner-Earnings is ranked lower than
83% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 36.31 vs. ABMD: 90.48 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABMD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 44.38  Med: 98.44 Max: 201.19
Current: 90.48
44.38
201.19
PB Ratio 12.74
ABMD's PB Ratio is ranked lower than
94% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. ABMD: 12.74 )
Ranked among companies with meaningful PB Ratio only.
ABMD' s PB Ratio Range Over the Past 10 Years
Min: 1.58  Med: 5.86 Max: 14.19
Current: 12.74
1.58
14.19
PS Ratio 15.58
ABMD's PS Ratio is ranked lower than
87% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.32 vs. ABMD: 15.58 )
Ranked among companies with meaningful PS Ratio only.
ABMD' s PS Ratio Range Over the Past 10 Years
Min: 2.38  Med: 6.61 Max: 17.76
Current: 15.58
2.38
17.76
Price-to-Free-Cash-Flow 105.64
ABMD's Price-to-Free-Cash-Flow is ranked lower than
88% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 32.13 vs. ABMD: 105.64 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABMD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 23.56  Med: 63.5 Max: 1172.38
Current: 105.64
23.56
1172.38
Price-to-Operating-Cash-Flow 59.01
ABMD's Price-to-Operating-Cash-Flow is ranked lower than
90% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 19.50 vs. ABMD: 59.01 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABMD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 21.72  Med: 52.46 Max: 430.93
Current: 59.01
21.72
430.93
EV-to-EBIT 68.64
ABMD's EV-to-EBIT is ranked lower than
88% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 24.67 vs. ABMD: 68.64 )
Ranked among companies with meaningful EV-to-EBIT only.
ABMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -305.5  Med: 28.2 Max: 694.7
Current: 68.64
-305.5
694.7
EV-to-EBITDA 64.03
ABMD's EV-to-EBITDA is ranked lower than
91% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 17.99 vs. ABMD: 64.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -397.6  Med: 27.65 Max: 727.3
Current: 64.03
-397.6
727.3
EV-to-Revenue 14.75
ABMD's EV-to-Revenue is ranked lower than
84% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. ABMD: 14.75 )
Ranked among companies with meaningful EV-to-Revenue only.
ABMD' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.7  Med: 6.2 Max: 17.5
Current: 14.75
1.7
17.5
PEG Ratio 1.38
ABMD's PEG Ratio is ranked higher than
63% of the 83 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. ABMD: 1.38 )
Ranked among companies with meaningful PEG Ratio only.
ABMD' s PEG Ratio Range Over the Past 10 Years
Min: 1.27  Med: 1.46 Max: 1.93
Current: 1.38
1.27
1.93
Shiller PE Ratio 527.87
ABMD's Shiller PE Ratio is ranked lower than
100% of the 53 Companies
in the Global Medical Devices industry.

( Industry Median: 49.44 vs. ABMD: 527.87 )
Ranked among companies with meaningful Shiller PE Ratio only.
ABMD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 455.58  Med: 862.39 Max: 12369
Current: 527.87
455.58
12369
Current Ratio 5.95
ABMD's Current Ratio is ranked higher than
77% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.64 vs. ABMD: 5.95 )
Ranked among companies with meaningful Current Ratio only.
ABMD' s Current Ratio Range Over the Past 10 Years
Min: 3.18  Med: 6.73 Max: 32.71
Current: 5.95
3.18
32.71
Quick Ratio 5.32
ABMD's Quick Ratio is ranked higher than
79% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ABMD: 5.32 )
Ranked among companies with meaningful Quick Ratio only.
ABMD' s Quick Ratio Range Over the Past 10 Years
Min: 2  Med: 5.62 Max: 31.29
Current: 5.32
2
31.29
Days Inventory 155.10
ABMD's Days Inventory is ranked lower than
60% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 128.08 vs. ABMD: 155.10 )
Ranked among companies with meaningful Days Inventory only.
ABMD' s Days Inventory Range Over the Past 10 Years
Min: 138.81  Med: 154.05 Max: 314.91
Current: 155.1
138.81
314.91
Days Sales Outstanding 41.17
ABMD's Days Sales Outstanding is ranked higher than
82% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. ABMD: 41.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.17  Med: 54.23 Max: 87.14
Current: 41.17
41.17
87.14
Days Payable 60.27
ABMD's Days Payable is ranked higher than
76% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 54.45 vs. ABMD: 60.27 )
Ranked among companies with meaningful Days Payable only.
ABMD' s Days Payable Range Over the Past 10 Years
Min: 60.27  Med: 97.03 Max: 218.64
Current: 60.27
60.27
218.64

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.00
ABMD's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. ABMD: -3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.9  Med: -4.8 Max: -0.5
Current: -3
-14.9
-0.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 43.49
ABMD's Price-to-Net-Cash is ranked lower than
83% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 15.73 vs. ABMD: 43.49 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ABMD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.29  Med: 10.91 Max: 73.96
Current: 43.49
1.29
73.96
Price-to-Net-Current-Asset-Value 27.19
ABMD's Price-to-Net-Current-Asset-Value is ranked lower than
88% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 6.83 vs. ABMD: 27.19 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ABMD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.08  Med: 7.11 Max: 28.5
Current: 27.19
1.08
28.5
Price-to-Tangible-Book 13.93
ABMD's Price-to-Tangible-Book is ranked lower than
87% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 3.98 vs. ABMD: 13.93 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ABMD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1  Med: 5.43 Max: 16.32
Current: 13.93
1
16.32
Price-to-Intrinsic-Value-Projected-FCF 7.04
ABMD's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
82% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. ABMD: 7.04 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABMD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.39  Med: 7.5 Max: 163.8
Current: 7.04
4.39
163.8
Price-to-Median-PS-Value 2.35
ABMD's Price-to-Median-PS-Value is ranked lower than
90% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. ABMD: 2.35 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABMD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 1.09 Max: 6.39
Current: 2.35
0.34
6.39
Price-to-Peter-Lynch-Fair-Value 3.86
ABMD's Price-to-Peter-Lynch-Fair-Value is ranked lower than
84% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. ABMD: 3.86 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ABMD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 2.31  Med: 4.21 Max: 35.22
Current: 3.86
2.31
35.22
Price-to-Graham-Number 7.73
ABMD's Price-to-Graham-Number is ranked lower than
91% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. ABMD: 7.73 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ABMD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.99  Med: 6.13 Max: 15.52
Current: 7.73
2.99
15.52
Earnings Yield (Greenblatt) % 1.49
ABMD's Earnings Yield (Greenblatt) % is ranked higher than
52% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. ABMD: 1.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABMD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -24  Med: 0.2 Max: 3.7
Current: 1.49
-24
3.7
Forward Rate of Return (Yacktman) % 59.59
ABMD's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.78 vs. ABMD: 59.59 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABMD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -40.8  Med: 0.4 Max: 77.9
Current: 59.59
-40.8
77.9

More Statistics

Revenue (TTM) (Mil) $474.78
EPS (TTM) $ 1.70
Beta-0.38
Short Percentage of Float4.01%
52-Week Range $95.14 - 160.10
Shares Outstanding (Mil)44.10

Analyst Estimate

Mar18
Revenue (Mil $)
EPS ($) 2.06
EPS without NRI ($) 2.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ABMD

Headlines

Articles On GuruFocus.com
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure Sep 20 2017 
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure Sep 20 2017 
Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former Chief Financial Of Aug 28 2017 
Heart Recovery Patients Visit Capitol Hill to Advocate for Lifesaving Cardiovascular Technology Jun 09 2017 
Abiomed to Present at the Jefferies Healthcare Conference May 30 2017 
Abiomed Introduces 3rd Generation Impella CP® Heart Pumps at SCAI 2017 May 09 2017 
Abiomed Announces First Patient Enrolled in STEMI DTU Feasibility Study May 04 2017 
Abiomed Fourth Quarter Fiscal 2017 Earnings and Conference Call Notification Apr 13 2017 
Abiomed Marks Grand Opening of Newly-Expanded Headquarters in Danvers, Massachusetts Mar 30 2017 
7 Stocks That Are Outperforming the Market Mar 22 2017 

More From Other Websites
See what the IHS Markit Score report has to say about Abiomed Inc. Sep 21 2017
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure Sep 20 2017
3 Stocks That Could Soar More Than Priceline Sep 19 2017
ABIOMED, Inc. – Value Analysis (NASDAQ:ABMD) : September 2, 2017 Sep 01 2017
ABIOMED, Inc. breached its 50 day moving average in a Bearish Manner : ABMD-US : August 30, 2017 Aug 30 2017
Abiomed searches for new CFO after Tomsicek resigns Aug 28 2017
Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former Chief Financial... Aug 28 2017
ETFs with exposure to ABIOMED, Inc. : August 15, 2017 Aug 15 2017
Edited Transcript of ABMD earnings conference call or presentation 27-Jul-17 12:00pm GMT Aug 12 2017
IHS Markit Score Update: Drop in demand for ETFs holding Abiomed Inc is a negative sign for its... Aug 11 2017
Why ABIOMED (ABMD) Could Be Positioned for a Surge Aug 10 2017
Allscripts (MDRX) Meets Q2 Earnings Estimates, View Upbeat Aug 04 2017
PerkinElmer (PKI) Meets Q2 Earnings, Raises '17 Guidance Aug 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}